Justin A. Shields
Edmonton, AB T6G2H7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Identification of a Potent Pan-Coronaviral Main Protease Inhibitor.
Journal: Journal of medicinal chemistry
Published: July 16, 2026
Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models.
Journal: Science advances
Published: May 29, 2026
Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease.
Journal: ACS medicinal chemistry letters
Published: September 05, 2024
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
Journal: RSC medicinal chemistry
Published: July 22, 2021
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability.
Journal: Journal of medicinal chemistry
Published: July 09, 2021
SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
Journal: Vaccine
Published: June 25, 2021
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies.
Journal: European journal of medicinal chemistry
Published: March 15, 2021
Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2.
Journal: Stem cell reports
Published: March 12, 2021
Author Correction: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Journal: Nature communications
Published: October 21, 2020
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Journal: Nature communications
Published: April 29, 2020
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
Journal: Scientific reports
Published: April 12, 2019
Highly bioavailable silibinin nanoparticles inhibit HCV infection.
Journal: Gut
Published: April 07, 2016
Last Updated: 09/26/2026